Turbine is at the forefront of drug development with its innovative Simulated Cell™ platform, which utilizes advanced computational biology to simulate biological experiments prior to actual implementation in cells, animals, or patients. This technology addresses the critical need for more efficient and accurate predictions regarding the efficacy of therapies, thereby guiding real-life experiments and minimizing costly failures throughout the research and development (R&D) process. By leveraging machine learning, Turbine's platform interprets complex protein interactions and other biological data, enabling it to predict responses in various models, including engineered cell lines and patient samples. This capability not only accelerates the R&D timeline but also enhances the understanding of biological mechanisms, allowing for the identification of the most promising hypotheses and necessary validation experiments.

In addition to its core simulation technology, Turbine collaborates with pharmaceutical companies to uncover novel therapeutic targets and optimize drug development processes. The company’s approach includes in vitro and in vivo validation studies, which are essential for confirming the computational predictions made by its Simulated Cell™ platform. By focusing on patient biology and employing a data-driven methodology, Turbine aims to improve the success rates of novel therapies and ensure that existing treatments are effectively targeted to the right patient populations. This commitment to integrating AI with molecular biology positions Turbine as a leader in transforming the landscape of oncology research and development.

Hungary

Turbine develops an AI platform that simulates cancer behavior, designs effective therapies, and increases clinical success rates using digital cell models, cell behavior simulation technology, and molecular biology.

Turbine

Company Details